Clinical Trials Directory

People in this study will be in one of two groups. One group will get a medicine called ABBV-400 through an IV every 21 days. The other group will not get medicine but will have blood tests for cancer DNA and imaging scans to check for cancer.

What happens in this study? - You'll get the study medicine through an IV every 3 weeks - Depending on your group, you might also get: - Budigalimab (a new medicine being tested) - Or a standard cancer medicine - You'll give blood and urine samples - You'll have regular CT or MRI scans to check your health

We are doing this study to collect information about people with oligometastasis for future use.

We are doing this study to find out if carefully watching patients with low risk germ cell tumors after surgery will have different results than treating people with chemotherapy afer their surgery. For people who are in standard risk groups related to germ cell tumors, we want to compare the effects of carboplatin with cisplatin and find out which of these drugs seems to work better.

We are doing this study to see if combining immunotherapy with chemotherapy is a better treatment than chemotherapy alone for NSCLC.

We are doing this study to find out if an experimental drug called Lutetium Lu 177 dotatate (the study drug) has the potential to shrink or stabilize bronchial neuroendocrine tumors. We will compare how the study drug works to everolimus, which is the usual drug used for this diagnosis.

We are doing this study to find out if a medical technology called the Signatera blood test can help doctors and patients determine the best course of treatment for bladder cancer after the patient has a radical cystectomy (removal of the bladder and surrounding lymph nodes). The Signatera test is used to detect cancer DNA in the blood before cancer can be seen using imaging (like MRI or CT scans).

This study has two groups based on a test called the Signatera test. People in Group A have a positive test. They will be placed by chance into one of two treatment groups. One group will get a medicine called nivolumab. The other group will get two medicines, nivolumab and relatlimab. These medicines are given through a vein once every 28 days, and people can get up to 12 cycles. People in Group B have a negative test. They will be placed by chance into one of two choices. One choice is to get nivolumab right away, given through a vein once every 28 days for up to 12 cycles. The other choice is close monitoring without starting medicine right away. If their Signatera test changes from negative to positive, they will then be offered nivolumab for up to 12 cycles.